Biocon's shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to 'Buy' with a target price of ₹430, ...

Shares of Biocon soared over 4 percent on January 13 after the US Food and Drug Administration cleared arm Biocon Biologics' insulin facility in Malaysia, putting an end to a major regulatory ...

The regulator found that Goldman Sachs’ acquisition of optionally convertible debentures (OCDs) in Biocon, which would have translated to a 3.81 per cent stake in the company on a fully diluted ...

Kiran Mazumdar-Shaw, Chairperson of major drugmaker Biocon Ltd., urged the government to eliminate tax on drugs for cancer treatment and for chronic and rare diseases, ahead of the budget 2025 ...

A collection of the most-viewed Moneycontrol videos. Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting ...

Shares of Biocon Ltd climbed 7 per cent in Tuesday's trade, with the nearing its September 2024 high of Rs 395.65, after HSBC upgraded the stock to 'Buy' from 'Reduce' earlier. The foreign ...

Biotechnology company Biocon Ltd stated on Thursday (January 2) that its wholly owned subsidiary, Biocon Pharma Ltd, has acquired permission from the National Medical Products Administration (NMPA ...

Biocon Ltd has hired more top executives in its generics business, Maninder Kapoor Puri, head of human resources said. “As Biocon's generics business grows in key markets and secures approvals ...

Founded in 2022, Bengaluru-based Fermbox Bio uses precision fermentation and synthetic biology to programme microorganisms and produce bio-based enzymes and technologies to manufacture biofuels ...

Biocon share price rose 4.5% following US FDA clearance for its Malaysian insulin facility, resolving a regulatory bottleneck ...

Kiran Mazumdar Shaw, chairperson, Biocon and Biocon Biologics said that the sector’s impressive growth trajectory, with pharmaceutical exports crossing $2.3 billion in July 2024, highlights its ...

Indian firms such as Sun Pharma, Dr. Reddy’s, Laboratories and Biocon are set to gain from this. Beyond generics, biosimilars present another growth avenue. "The upcoming patent expirations will ...